{"id":"mva-bn-filo-1-10-8-infectious-unit-inf-u","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site pain or erythema"},{"rate":null,"effect":"Myalgia"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fever"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This vaccine uses a non-replicating viral vector (MVA) engineered to express surface glycoproteins from Ebola and Marburg viruses. It stimulates both cellular and humoral immune responses, training T cells and B cells to recognize filoviral antigens before natural infection occurs. MVA-BN-Filo is typically used as a prime in heterologous prime-boost vaccination regimens to establish broad immunity against filovirus infection.","oneSentence":"MVA-BN-Filo is a recombinant modified vaccinia Ankara (MVA) vaccine expressing Filovirus glycoproteins that primes the immune system to recognize and respond to Ebola and Marburg viruses.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:50:15.005Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of Ebola virus disease"},{"name":"Prevention of Marburg virus disease"}]},"trialDetails":[],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"MVA-BN-Filo 1*10^8 Infectious Unit [Inf. U.]","genericName":"MVA-BN-Filo 1*10^8 Infectious Unit [Inf. U.]","companyName":"Janssen Vaccines & Prevention B.V.","companyId":"janssen-vaccines-prevention-b-v","modality":"Biologic","firstApprovalDate":"","aiSummary":"MVA-BN-Filo is a recombinant modified vaccinia Ankara (MVA) vaccine expressing Filovirus glycoproteins that primes the immune system to recognize and respond to Ebola and Marburg viruses. Used for Prevention of Ebola virus disease, Prevention of Marburg virus disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":false,"score":3}}